Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory syncytial virus
Biotech
Enanta sees RSV drug fail phase 2b but finds positives
With some analyses generating signs of efficacy, the biotech made the case that the data support further development of the direct-acting antiviral.
Nick Paul Taylor
Sep 29, 2025 8:05am
Gilead blames low infection rates for ending 2 RSV trials
Jun 27, 2025 4:09am
Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial
Jan 30, 2025 5:32am
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
Dec 9, 2024 9:35am
Pfizer lets its RSV pipeline dry up in crowded space
Oct 29, 2024 11:23am
Vicebio hauls in $100M series B to push RSV shot through phase 1
Sep 23, 2024 3:00am
